Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

AZ drug matched to cancer mutation passes phase 2 test

More data from promising class of targeted small molecule drugs

- PMLiVE

Healthcare sector bullish despite political uncertainty

Targeted and gene therapies rated as major advances ahead of Jefferies conference in London

World Diabetes Day: Interaction and impact of diabetes on mental health

For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...

Mednet

- PMLiVE

Decision time for Brexit

Pharma fears a no deal Brexit - but compromise deal has opponents on both sides

- PMLiVE

Entering the era of digital trials

How technology is transforming the design, conduct and analysis of clinical research

Emerging Technologies

Four Health hosted an event on Emerging Technologies.

Four Agency Worldwide

- PMLiVE

Porterhouse enhances its client services and creative teams with a double recruitment

At Porterhouse Medical Group we are delighted to announce that we have strengthened our team once again, by welcoming two new members to our UK offices in Reading. Joining our...

Porterhouse Medical Group

Five Steps to Well-Being

International Stress Awareness Week – putting principles into practice at Porterhouse

As a busy, fast-paced agency, Porterhouse Medical Group recognises that stress can affect anyone, at any time. With this in mind, we have a number of measures in place to...

Porterhouse Medical Group

- PMLiVE

Roche gains speedy review for Tecentriq in first-line breast cancer

Set to become the first immunotherapy for triple negative breast cancer

- PMLiVE

Duchenne UK backs Evox dystrophin delivery project

Funding will drive preclinical studies on dystrophin-bearing exosomes

- PMLiVE

Brexit to blame as firm plans to leave UK for Ireland

Tax-inversion deal brought company to UK - now Brexit causes a re-think

- PMLiVE

AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

AZ continues sell-off, SOBI spies US expansion

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links